Resultats globals: 8 registres trobats en 0.01 segons.
Articles, 8 registres trobats
Articles 8 registres trobats  
1.
16 p, 1.2 MB Deucravacitinib in Moderate to Severe Psoriasis : Clinical and Quality-of-Life Outcomes in a Phase 2 Trial / Thaçi, Diamant (University of Luebeck) ; Strober, Bruce (Yale University) ; Gordon, Kenneth B. (Medical College of Wisconsin) ; Foley, Peter (The University of Melbourne) ; Gooderham, Melinda (Queen's University and Probity Medical Research) ; Morita, Akimichi (Nagoya City University) ; Papp, Kim A. (Clinical Research and Probity Medical Research) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Menter, M. Alan (Baylor University Medical Center) ; Colombo, Matthew J. (Bristol Myers Squibb) ; Elbez, Yedid (Bristol Myers Squibb) ; Kisa, Renata M. (Bristol Myers Squibb) ; Ye, June (Bristol Myers Squibb) ; Napoli, Andrew A. (Bristol Myers Squibb) ; Wei, Lan (Bristol Myers Squibb) ; Banerjee, Subhashis (Bristol Myers Squibb) ; Merola, Joseph F. (Harvard Medical School) ; Gottlieb, Alice B. (Icahn School of Medicine at Mount Sinai) ; Universitat Autònoma de Barcelona
Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis. [...]
2022 - 10.1007/s13555-021-00649-y
Dermatology and Therapy, Vol. 12 (january 2022) , p. 495-510  
2.
14 p, 1.5 MB Treatment Options and Goals for Patients with Generalized Pustular Psoriasis / Krueger, James (The Rockefeller University) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Thaçi, Diamant (University of Lübeck) ; Universitat Autònoma de Barcelona
Generalized pustular psoriasis (GPP) is a rare, severe neutrophilic skin disorder characterized by sudden widespread eruption of superficial sterile pustules with or without systemic inflammation. GPP flares can be life-threatening if untreated due to potential severe complications such as cardiovascular failure and serious infections. [...]
2022 - 10.1007/s40257-021-00658-9
American Journal of Clinical Dermatology, Vol. 23 (january 2022) , p. 51-64  
3.
13 p, 3.0 MB Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase clinical trials (re 1 and re 2) through 148 weeks / Reich, K. (Dermatologikum Berlin) ; Warren, R. B. (The University of Manchester. Manchester NIHR Biomedical Research Centre. Salford Royal NHS Foundation Trust) ; Iversen, L. (Aarhus University Hospital (Aarhus, Dinamarca)) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Pau-Charles, I. (Almirall R&D) ; Igarashi, A. (NTT Medical Center Tokyo) ; Ohtsuki, M. (Jichi Medical University) ; Falqués, M. (Almirall R&D) ; Harmut, M. (Almirall R&D) ; Rozzo, S. (Sun Pharmaceuticals) ; Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ; Cantrell, W. (University of Alabama at Birmingham) ; Blauvelt, A. (Oregon Medical Research Center) ; Thaçi, Diamant (University of Lübeck) ; Universitat Autònoma de Barcelona
Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. [...]
2019 - 10.1111/bjd.18232
British journal of dermatology, Vol. 182 (july 2019) , p. 605-617  
4.
14 p, 1.3 MB Infections in Dupilumab Clinical Trials in Atopic Dermatitis : A Comprehensive Pooled Analysis / Eichenfield, L. F. (Division of Pediatric and Adolescent Dermatology. Rady Children's Hospital) ; Bieber, T. (Department of Dermatology and Allergy. Christine Kühne-Center for Allergy Research and Education. University of Bonn) ; Beck, L. A. (Department of Dermatology. University of Rochester Medical Center) ; Simpson, E. L. (Department of Dermatology. Oregon Health and Science University) ; Thaçi, Diamant (Comprehensive Center for Inflammation Medicine. University Hospital Schleswig-Holstein) ; de Bruin-Weller, Marjolein (University Medical Center Utrecht) ; Deleuran, Mette (Aarhus University Hospital (Aarhus, Dinamarca)) ; Silverberg, J. I. (Northwestern University Feinberg School of Medicine) ; Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Fölster-Holst, R. (University Hospital Schleswig-Holstein. Dermatology) ; Chen, Z. (Regeneron Pharmaceuticals. Inc.) ; Graham, N. M. H. (Regeneron Pharmaceuticals. Inc.) ; Pirozzi, G. (Sanofi) ; Akinlade, B. (Regeneron Pharmaceuticals. Inc.) ; Yancopoulos, G. D. (Regeneron Pharmaceuticals. Inc.) ; Ardeleanu, M. (Regeneron Pharmaceuticals. Inc.) ; Universitat Autònoma de Barcelona
Background: Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e. g. , anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. [...]
2019 - 10.1007/s40257-019-00445-7
American Journal of Clinical Dermatology, Vol. 20 Núm. 3 (january 2019) , p. 443-456  
5.
9 p, 453.9 KB Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis : pooled analysis across six clinical trials / Strober, B. E. (Probity Medical Research) ; Gottlieb, A. B. (New York Medical College at Metropolitan Hospital) ; van de Kerkhof, P. C. M. (Radboud University Nijmegen Medical Centre) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Bachelez, Hervé (Sorbonne Paris Cité Université Paris Diderot. Assistance Publique-Hôpitaux de Paris. Service de Dermatologie. Hôpital Saint-Louis) ; Chouela, E. (Universidad de Buenos Aires) ; Imafuku, S. (Department of Dermatology. Faculty of Medicine. Fukuoka University) ; Thaçi, Diamant (Comprehensive Center for Inflammation Medicine. University Hospital Schleswig-Holstein) ; Tan, H. (Pfizer Inc.) ; Valdez, H. (Pfizer Inc.) ; Gupta, P. (Pfizer Inc.) ; Kaur, M. (Pfizer Inc.) ; Frajzyngier, V. (Pfizer Inc.) ; Wolk, R. (Pfizer Inc.) ; Universitat Autònoma de Barcelona
Background: Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate-to-severe chronic plaque psoriasis. [...]
2019 - 10.1111/bjd.17149
British journal of dermatology, Vol. 180 Núm. 1 (january 2019) , p. 67-75  
6.
5 p, 332.3 KB Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study / Thaçi, Diamant (Research Institute and Comprehensive Center for Inflammation Medicine. University of Luebeck) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Reich, K. (Dermatologikum Berlin and SCIderm Research Institute) ; Tsai, T. F. (National Taiwan University Hospital (Taipei, Taiwan)) ; Tyring, S. (University of Texas Health Science Center and Center for Clinical Studies) ; Kingo, K. (Tartu University Hospital (Tartu, Estònia)) ; Ziv, M. (Emek Medical Center) ; Pinter, A. (Department of Dermatology. University of Frankfurt) ; Vender, R. (Venderm Innovations in Psoriasis) ; Lacombe, A. (Novartis Pharma AG) ; Xia, S. (Novartis Beijing Novartis Pharma Co Ltd) ; Bhosekar, V. (Novartis Healthcare Pvt Ltd) ; Gilloteau, I. (Novartis Pharma AG) ; Guana, A. (Novartis Pharmaceuticals Corporation) ; Blauvelt, A. (Oregon Medical Research Center) ; Universitat Autònoma de Barcelona
2019 - 10.1016/j.jaad.2019.04.045
Journal of the American Academy of Dermatology, Vol. 81 Núm. 6 (december 2019) , p. 1405-1409  
7.
9 p, 310.0 KB Long-term safety and tolerability of apremilast in patients with psoriasis : Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) / Crowley, Jeffrey (Bakersfield Dermatology) ; Thaçi, Diamant (Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein) ; Joly, Pascal (Department of Dermatology, Hôpital Charles Nicolle, Université de Rouen) ; Peris, Ketty (Universitá Cattolica del Sacro Cuore, Roma) ; Papp, Kim A. (Probity Medical Research, Waterloo) ; Gonçalves, Joana (Celgene Corporation) ; Day, Robert M. (Celgene Corporation) ; Chen, Rongdean (Celgene Corporation) ; Shah, Kamal (Celgene Corporation) ; Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cather, Jennifer C. (Modern Research Associates, Dallas) ; Universitat Autònoma de Barcelona
BACKGROUND: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. OBJECTIVE: Assess long-term safety of oral apremilast in psoriasis patients. [...]
2017 - 10.1016/j.jaad.2017.01.052
Journal of the American Academy of Dermatology, Vol. 77 Núm. 2 (2017) , p. 310  
8.
15 p, 1.4 MB Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy / Segaert, Siegfried (Leuven, Belgium) ; Shear, Neil H. (Toronto, Canada) ; Chiricozzi, Andrea (Pisa, Italy) ; Thaçi, Diamant (Lübeck, Germany) ; Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Young, Helen S. (Manchester, UK) ; Descamps, Vincent (Paris, France) ; Universitat Autònoma de Barcelona
Fixed-dose combination topical therapy with corticosteroid and vitamin D analog provides effective treatment and possible long-term management of psoriasis. The anti-inflammatory and immunomodulatory effects of corticosteroids and vitamin D analogs in treating psoriasis are well investigated; their complementary effects lead to the disruption of the inflammatory feedback loop underlying psoriasis pathogenesis. [...]
2017 - 10.1007/s13555-017-0196-z
Dermatology and Therapy, Vol. 7 (august 2017) , p. 265-279  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.